The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval is an ...

AI can call the shots on drug making because it 'doesn't have a career at stake,' major pharma CEO says Sanofi's CEO said the ...

Lupin is introducing Minzoya (levonorgestrel and ethinyl estradiol tablets and ferrous bisglycinate tablets), 0.1 mg/0.02 mg and 36.5 mg, which is a generic of Avion’s Balcoltra. Generic Minzoya ...

DNA Web Team Updated : Mar 17, 2018, 03:28 AM IST The European Medicines Agency has recommended the recall of all batches of generic Plavix from Swiss drugmaker Acino made at a factory in India, due ...

The boss of French pharmaceuticals giant Sanofi is convinced the rest of the world will follow its lead to Australia to take advantage of our nation’s scientific expertise. Paul Hudson, chief ...

Even quaint corners of the country are seeing a rise in drug violence and crime. Just ask the mayor of Morlaix, which has a population of about 15,000. By Richard Fausset Reporting from Morlaix ...

December 23, 2024, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) receptor ...

Substance abuse in the United States is one of the leading health conditions impacting millions of lives and due to many types of drug addictions. Since 2000, there have been 700,000 overdose deaths ...

A BMJ investigation highlights data integrity issues in the PLATO trial for ticagrelor, a drug approved by the FDA despite concerns ... or stroke compared with clopidogrel (Plavix). However, in US ...

The High Court has settled a 16-year battle between the federal government and Sanofi over alleged excess subsidies it paid after a judge blocked the release of a generic version of blood thinner ...